A detailed history of Geode Capital Management, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,264,166 shares of TRVI stock, worth $5.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,264,166
Previous 1,146,748 10.24%
Holding current value
$5.12 Million
Previous $3.42 Million 23.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$2.58 - $3.51 $302,938 - $412,137
117,418 Added 10.24%
1,264,166 $4.22 Million
Q2 2024

Aug 09, 2024

BUY
$2.44 - $3.36 $607,030 - $835,910
248,783 Added 27.71%
1,146,748 $3.42 Million
Q1 2024

May 13, 2024

BUY
$1.3 - $3.7 $62,509 - $177,910
48,084 Added 5.66%
897,965 $3.1 Million
Q4 2023

Feb 13, 2024

BUY
$1.06 - $2.05 $65,975 - $127,594
62,241 Added 7.9%
849,881 $1.14 Million
Q3 2023

Nov 13, 2023

BUY
$2.11 - $2.47 $18,608 - $21,782
8,819 Added 1.13%
787,640 $1.72 Million
Q2 2023

Aug 11, 2023

BUY
$1.8 - $3.44 $954,950 - $1.83 Million
530,528 Added 213.67%
778,821 $1.86 Million
Q1 2023

May 15, 2023

BUY
$1.69 - $2.97 $62,100 - $109,135
36,746 Added 17.37%
248,293 $459,000
Q4 2022

Feb 13, 2023

BUY
$1.61 - $2.42 $18,234 - $27,408
11,326 Added 5.66%
211,547 $408,000
Q3 2022

Nov 14, 2022

BUY
$1.54 - $4.28 $7,815 - $21,721
5,075 Added 2.6%
200,221 $308,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.39 $220,323 - $414,942
122,402 Added 168.26%
195,146 $548,000
Q1 2022

May 13, 2022

BUY
$0.46 - $2.48 $10,886 - $58,694
23,667 Added 48.22%
72,744 $160,000
Q3 2020

Nov 13, 2020

BUY
$3.5 - $7.62 $25,074 - $54,589
7,164 Added 17.09%
49,077 $197,000
Q1 2020

May 14, 2020

BUY
$1.71 - $5.87 $737 - $2,529
431 Added 1.04%
41,913 $137,000
Q2 2019

Aug 14, 2019

BUY
$7.5 - $10.12 $311,115 - $419,797
41,482 New
41,482 $311,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $236M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.